CV Sciences (CVSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, will be held virtually to enhance accessibility and safety for all shareholders.
Shareholders will vote on electing three directors, approving a reverse stock split, and ratifying the independent auditor.
Proxy materials are primarily distributed electronically to conserve resources and reduce costs.
The Board recommends voting in favor of all proposals and director nominees.
Voting matters and shareholder proposals
Proposal 1: Elect three directors to serve until the next annual meeting or until successors are qualified.
Proposal 2: Approve a reverse stock split at a ratio between 1-for-10 and 1-for-800, at the Board's discretion, any time before May 30, 2029.
Proposal 3: Ratify Haskell & White LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
No dissenters' rights are available for any proposal.
Shareholder proposals for the 2027 meeting must be received by December 12, 2026, to be considered.
Board of directors and corporate governance
Board consists of Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle, all nominated for re-election.
Board has compensation, audit, and nominating committees, each with defined charters and responsibilities.
Audit and compensation committees are composed of independent directors as defined by Nasdaq rules.
Board oversees management, strategic direction, and risk, with regular meetings and high attendance.
Code of ethics applies to all directors, officers, and employees.
Latest events from CV Sciences
- Gross margin rose to 49% in 2025 as cost cuts and new products offset revenue declines.CVSI
Q4 202526 Mar 2026 - Gross margin reached 47% in Q2 2024 as revenue held steady and liquidity risks remained.CVSI
Q2 20241 Feb 2026 - Q3 revenue fell 5% to $3.9M; margin improved, but regulatory and liquidity risks persist.CVSI
Q3 202413 Jan 2026 - Gross margin and adjusted EBITDA improved in 2024, with new products driving future growth.CVSI
Q4 202426 Dec 2025 - Virtual meeting to vote on directors, auditor, executive pay, and governance proposals.CVSI
Proxy Filing2 Dec 2025 - Q1 2025 revenue fell but margins and losses improved; new launches and financing support growth.CVSI
Q1 202525 Nov 2025 - Record 50.9% gross margin and first positive adjusted EBITDA since 2019 amid regulatory headwinds.CVSI
Q2 202523 Nov 2025 - Q3 2025 revenue dropped 16% but margin rose to 48.5% amid regulatory and liquidity risks.CVSI
Q3 202517 Nov 2025